| Old Articles: <Older 3641-3650 Newer> |
|---|
 |
Bio-IT World
April 2007
Malorye Allison |
Biomarkers versus Blockbusters Are companies really changing their strategies and using biomarkers to target smaller, better defined patient sets with their new drugs? Or is the vast majority of pharma biomarker studies just aimed at culling bad drugs from their pipelines?   |
Bio-IT World
April 2007
Leach & Tedeschi |
If THEY Build It, THEY Will Come Biopharma companies have many lessons to learn from the emerging and maturing Web 2.0 technologies. While social networking will help foster the exchange of ideas, sharing data remains one of the biopharma industry's greatest challenges. |
Bio-IT World
April 2007
Kevin Davies |
Closing the Compliance Loop Content management firm QUMAS is expanding into the regulatory realm for life science organizations. |
Bio-IT World
April 2007
Deborah Borfitz |
EDC Guru Moves from Novartis to Kendle The publicly owned clinical research organization Kendle recently brought the pragmatic Sylva Collins on board to provide leadership for its global biometrics offerings and help it become "the unparalleled leader in e-clinical services." |
Bio-IT World
April 2007
Ann Neuer |
Through the Gateway to FDA The central concept of the Electronic Submissions Gateway is to allow for a level playing field so that all communities -- drug, device, biologics, foods, veterinary medicine, and all strata of corporate environments, small pharma, big pharma, venture capital, and academia -- can play. |
Bio-IT World
April 2007
Deborah Borfitz |
Fusion Makes the Difference at Oracle With Fusion, Oracle will begin combining the best features of its JD Edwards, Siebel, and E-Business Suite product lines to form a new collection of web-based applications based on service-oriented architecture. Many life science companies globally run Oracle applications. |
Bio-IT World
April 2007
John Russell |
Whatever Happened to the Critical Path? Science progresses at its own rate and medical science is necessarily more cautious than other branches. But it feels like the lack of money and mindshare are turning the FDA's Critical Path Initiative into just another umbrella project. |
Wired
April 24, 2007
Monya Baker |
Pharm-Fresh Medicine Drugs being made inside plants and animals. |
The Motley Fool
April 23, 2007
Brian Lawler |
Trimeris Isn't Tumbling Trimeris announces first-quarter sales numbers for its HIV drug Fuzeon. Shares of the company were up 25% last week after it reported stronger-than-expected sales of the fusion inhibitor. |
The Motley Fool
April 23, 2007
Brian Lawler |
Neurochem Sets Low Expectations The specialty drug developer announces an update on plans to release results from a clinical study. Investors, take note. |
| <Older 3641-3650 Newer> Return to current articles. |
